From Wikipedia, the free encyclopedia
Jump to: navigation, search
Trifluridine structure.svg
Systematic (IUPAC) name
1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5- (trifluoromethyl) pyrimidine-2,4-dione
Clinical data
Trade names Viroptic
AHFS/ monograph
  • US: C (Risk not ruled out)
Eye drops
Pharmacokinetic data
Half-life 12 minutes
70-00-8 YesY
PubChem CID 6256
DrugBank DB00432 YesY
ChemSpider 6020 YesY
KEGG D00391 YesY
Chemical data
Formula C10H11F3N2O5
296.2 g/mol
 N (what is this?)  (verify)

Trifluridine (also called trifluorothymidine or TFT) is an anti-herpesvirus antiviral drug, used primarily on the eye. It was sold under the trade name, Viroptic, by Glaxo Wellcome, now merged into GlaxoSmithKline. The brand is now owned by Monarch Pharmaceuticals, which is wholly owned by King Pharmaceuticals.

It is a nucleoside analogue, a modified form of deoxyuridine, similar enough to be incorporated into viral DNA replication, but the -CF3 group added to the uracil component blocks base pairing.

It is a component of the experimental anti-cancer drug TAS-102.

A Cochrane Systematic Review showed that trifluridine was a more effective treatment than idoxuridine or vidarabine, significantly increasing the relative number of successfully healed eyes in 14 days.[1]



  1. ^ Wilhelmus KR (2010). "Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis". Cochrane Database Syst Rev 12: CD002898. doi:10.1002/14651858.CD002898.pub4. PMID 21154352. 
  2. ^ Heidelberger, C.; Parsons, D.; Remy, D. C. (1962). "Syntheses of 5-Trifluoromethyluracil and 5-Trifluoromethyl-2″-Deoxyuridine". Journal of the American Chemical Society 84 (18): 3597. doi:10.1021/ja00877a046.  edit
  3. ^ Heidelberger, C.; Parsons, D. G.; Remy, D. C. (1964). "Syntheses of 5-Trifluoromethyluracil and 5-Trifluoromethyl-2'-deoxyuridine1,2". Journal of Medicinal Chemistry 7: 1. doi:10.1021/jm00331a001.  edit

External links[edit]

  • Costin D, Dogaru M, Popa A, Cijevschi I (2004). "Trifluridine therapy in herpetic in keratitis". Rev Med Chir Soc Med Nat Iasi 108 (2): 409–12. PMID 15688823. 
  • Kuster P, Taravella M, Gelinas M, Stepp P (1998). "Delivery of trifluridine to human cornea and aqueous using collagen shields.". CLAO J 24 (2): 122–4. PMID 9571274. 
  • O'Brien W, Taylor J (1991). "Therapeutic response of herpes simplex virus-induced corneal edema to trifluridine in combination with immunosuppressive agents.". Invest Ophthalmol Vis Sci 32 (9): 2455–61. PMID 1907950. 
  • "Trifluridine Ophthalmic Solution, 1%" (PDF). Retrieved 2007-03-24.